John C.M. Farquhar Sells 15,560 Shares of Heartflow (NASDAQ:HTFL) Stock

Heartflow, Inc. (NASDAQ:HTFL) CEO John C.M. Farquhar sold 15,560 shares of the business’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $39.06, for a total transaction of $607,773.60. Following the completion of the transaction, the chief executive officer directly owned 420,720 shares in the company, valued at $16,433,323.20. This trade represents a 3.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John C.M. Farquhar also recently made the following trade(s):

• On Monday, August 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $28.31, for a total transaction of $638,730.22.
• On Friday, July 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $27.75, for a total transaction of $626,095.50.
• On Wednesday, June 24th, John C.M. Farquhar sold 38,900 shares of Heartflow stock. The shares were sold at an average price of $35.00, for a total transaction of $1,361,500.00.
• On Wednesday, June 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $28.50, for a total value of $643,017.00.

Heartflow Price Performance

Shares of HTFL stock traded up $3.29 during trading hours on Tuesday, hitting $45.23. The stock had a trading volume of 4,168,269 shares, compared to its average volume of 1,510,340. The stock has a market capitalization of $3.90 billion and a price-to-earnings ratio of -24.72. Heartflow, Inc. has a one year low of $20.13 and a one year high of $45.33. The stock’s 50-day moving average price is $29.35 and its two-hundred day moving average price is $27.85.

Heartflow (NASDAQ:HTFL) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.15. Heartflow had a negative return on equity of 23.50% and a negative net margin of 55.82%.The business had revenue of $64.08 million during the quarter. The business’s revenue was up 47.7% on a year-over-year basis. As a group, equities research analysts predict that Heartflow, Inc. will post -0.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Heartflow

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. purchased a new stake in shares of Heartflow in the third quarter valued at $48,871,000. Legal & General Group Plc bought a new position in Heartflow during the 3rd quarter valued at about $59,000. Franklin Resources Inc. purchased a new stake in Heartflow in the 3rd quarter worth about $10,829,000. UBS Group AG bought a new position in shares of Heartflow during the third quarter valued at approximately $5,130,000. Finally, Sei Investments Co. purchased a new stake in shares of Heartflow in the third quarter worth approximately $303,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on HTFL shares. Wells Fargo & Company upped their price target on shares of Heartflow from $37.00 to $39.00 and gave the company an “overweight” rating in a research note on Friday. JPMorgan Chase & Co. boosted their target price on shares of Heartflow from $35.00 to $45.00 and gave the stock an “overweight” rating in a report on Friday. Morgan Stanley increased their price target on shares of Heartflow from $35.00 to $40.00 and gave the company an “equal weight” rating in a report on Friday. Benchmark reiterated a “buy” rating on shares of Heartflow in a research report on Friday. Finally, Stifel Nicolaus upped their price objective on Heartflow from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $43.43.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.